Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 141.85

+0.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (1620)	6/25/2006 3:32:41 AM
From: Robohogs	Read Replies (3) of 1834

Thanks. On doxepin, the phase IIIs were showing 40 mins improvement at day 29 in TST for high dose version (still lower than psyche doses) vs. 10 mins for placebo. If memory serves, indi 20 mg gave just over an hour vs. 30-40 mins for placebo and L gave something like 90 mins (high dose), again with a 30 min placebo effect. On a time to sleep basis, it appears the Somaxon crowd are normal folks as their baseline scores were 35-40 mins going to 25-30 mins. On L, the comparable numbers are 60 going to 30 mins. So it would appear the Somaxon crowd is not as bad off as the other crowds. The p scores are also in the several percent range for some scores while I think indi and L were mostly less than .0001 - partly a function of placebo moves, worse off patients for L and indi, and trial sizes but still there. Somaxon is touting their non-scheduled status, the non-gaba effect, their long-term studies, etc. This drug to me looks a lot like Rozerem and should get 5% of mkt. Key question is if docs/patients will take generic psyche drug low dosage form (10 mg) and cut in half to get 5 mg dosage (vs. 6 mg for Silenor). Hard to see this being a huge winner for Somaxon but it is probably a better buy than NBIX would be. Thanks Elisabeth. I guess I will stay with SEPR for now and pray for a buyout. On side effects, I had read in some research about hallucination/amnesia impacts but cannot find it in anything published by NBIX - not that one can find anything on their site and filings other than press releases/high level abstracts. I do know lunesta did have hallucination issues of 1-3% at 3 mg (and it apparently gets worse at 6 mg according to safety data in the label). Ambien, lunesta and indi also all cause euphoria at higher than prescribed doses per safety data. Jon

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next